rEECur

There is no translation available.

Trial for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

Agents: Four different chemotherapy regimens 
Phase II/III
Status  Open, recruiting 
Sponsor University of Birmingham

 

Further information: https://www.ucl.ac.uk/cancer/research/centres-and-networks/euro-ewing-consortium/clinical-trials/reecur/reecur-information

 

WHO is the trial for?
  • Patients with Ewing sarcoma that has come back after treatment
  • Patients with primary Ewing sarcoma that is not responding to therapy

WHAT is the key question that this trial is attempting to answer?

 The aim of the rEECur trial is to compare four different chemotherapy regimens to find out which is most effective and/or has fewest side effects.

WHY patients might want to participate?

 This trial will further support the research in Ewing’s sarcoma and potentially help other patients with this disease. The trial might or might not have benefit in your individual case. For more about the importance and benefits of joining clinical trials, please click here.

WHEN will the trial be open?

The study is open for participation (recruiting)

WHERE is the trial available?

The trial is available in several study centers in the in the UK, Spain, Italy, Finland, Norway, Denmark, France, Hungary, Belgium, Poland, Czech Republic, Netherlands, Switzerland, New Zealand and Australia across many sites.  

Study contact:

If you have any questions about this trial, please contact the Cancer Research UK Clinical Trials Unit at the University of Birmingham Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

STUDY DESIGN: What does the study look like?

The trial is comparing four treatments, also known as regimens or arms, called TC, IT, GD and IFOS.

  • Topotecan and cyclophosphamide (TC)
  • Irinotecan and temozolomide (IT)
  • Gemcitabine and docetaxel (GD)
  • Ifosfamide (IFOS)

These regimens are four commonly used treatments for recurrent Ewing sarcoma. The trial is being run as it is not known which is the best treatment for this group of patients.

More details about the trial scheme can be found here.

HOW do I get more information?

 Patient organisations supporting sarcoma patients in your country may offer additional information about the trial, current recruitment status, and key contacts. Click here for a list of patient organisations serving sarcoma patients. If there are no such organisation in your country, please email us for more information: Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.

SHARE your experience

   
You want to share your experience on this trial?
Send us an e-mail to: Cette adresse e-mail est protégée contre les robots spammeurs. Vous devez activer le JavaScript pour la visualiser.
Note that your experience would be helpful for other patients and patient organisations.

RESULTS of the study

  No results are available at this time. Future results will be linked here.

 

Disclaimer: This is a patient-friendly summary of the clinical trial which has been provided for informational purposes only. Patients should consult their physician about any clinical trial opportunity.

Merken